Superworth

Viemed Healthcare revenue VMD

Sales by quarter and over the last twelve months, from 2018.

Last 12 months, to Jun 30, 2026
$301.6M
Latest quarter, Q2 FY26
$78.1M
+24% on a year earlier
Fiscal year 2025
$270.3M
+21% on the year before

Viemed Healthcare's revenue was $301.6M over the twelve months to Jun 30, 2026, up 25% on a year earlier.

In its latest quarter, Q2 FY26, it was $78.1M, up 24% on the same quarter a year before.

Over the five fiscal years to FY2025 it grew 16% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$270.3M+21%
FY2024$224.3M+23%
FY2023$183M+32%
FY2022$138.8M+19%
FY2021$117.1M−11%
FY2020$131.3M+64%
FY2019$80.3M+24%
FY2018$64.5Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$78.1M+24%$301.6M
Q1 FY26$75.4M+28%$286.6M
Q4 FY25$76.2M+26%$270.3M
Q3 FY25$71.9M+24%$254.8M
Q2 FY25$63.1M+15%$240.9M
Q1 FY25$59.1M+17%$232.8M
Q4 FY24$60.7M+20%$224.3M
Q3 FY24$58M+17%$214.3M
Q2 FY24$55M+27%$205.7M
Q1 FY24$50.6M+28%$194M
Q4 FY23$50.7M+35%$183M
Q3 FY23$49.4M+38%$169.8M

Against its peers

Companies in Medical - Care Facilities nearest Viemed Healthcare's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
VMDViemed Healthcare$301.6M+25% a year
SBCSBC Medical$175.2M−7% a year
OMDAOmada Health$309.8M+48% a year
USPHU S Physical Therapy$812.2M+11% a year
PNTGPennant$1.1B+38% a year
ARDTArdent Health$6.4B+3% a year
HCSGHealthcare Services$1.9B+4% a year
PGNYProgyny$1.3B+6% a year
ADUSAddus HomeCare$1.5B+16% a year
MDPediatrix Medical$2B+1% a year
PRVAPrivia Health$2.4B+24% a year
Peer median$1.4B

Where Viemed Healthcare ranks

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Viemed Healthcare

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.